Evaluation of Breastmilk Microbiota as a Function for Immunity

Overview

The aim of this study is to evaluate the difference of breast milk microbiota between mothers with and without vaginal infections during pregnancy.

Full Title of Study: “Comparison of Microbiota Composition and Antimicrobial Property From Breastmilk of Mothers With and Without Pregnancy Vaginal Infections”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: November 30, 2021

Detailed Description

The maternal microbiota is one of the relevant factors in the development of the infant's immune system, whereby the colonization of microbes in human begins at birth, when the newborn baby is exposed to maternal vaginal, gastrointestinal microbiota and as well as the microbes from the external environment. The neonatal intestine is colonized by symbiotic bacteria can be divided into four main steps; (i) acquisition of maternal vaginal, colonic, and skin flora at birth; (ii) introduction of oral feedings (breastfeeding or formula feeding); (iii) weaning; and (iv) acquisition of complete adult colonization. Breastfeeding is associated with the protection of the infants from either infections or infection-related conditions, such as gastroenteritis, upper and lower respiratory tract infection, acute otitis media, urinary tract infection, neonatal septicaemia and necrotizing enterocoltis. The protection is through the combination of action of the breast milk components, such as maternal immunoglobulins, immunocompetent cells, or variety of anti-microbial compounds. Besides that, breast milk also contains prebiotic substances which may selectively stimulate the growth of limited number of beneficial bacteria in the gut. A total number of 100 lactating mothers are needed for this study. Subjects will be recruited from HUSM Kubang Kerian, USM Main Campus Penang, and Institut Perubatan & Pergigian Termaju USM Penang. The subjects will be explained on all related information in the consent form prior to signing. The procedure of collecting sample is hands must be washed before milk expression, and nipples are cleaned with sterile water and alcohol swab. 15mL of fresh breast milk will be collected into a tube and stored at -20℃ until further analyses.

Interventions

  • Other: Past history of vaginal Infections
    • With or without vaginal infection during pregnancy

Arms, Groups and Cohorts

  • Group A
    • Lactating women with vaginal infection during pregnancy as confirmed by past medical records
  • Group B
    • Lactating women without any vaginal infection during pregnancy

Clinical Trial Outcome Measures

Primary Measures

  • Breastmilk microbiota profiles
    • Time Frame: 6 months
    • Differences in breastmilk microbiota profiles via pyrosequencing from breastmilk of women with or without history of vaginal infection during pregnancy

Secondary Measures

  • Immuno-modulatory properties of breastmilk
    • Time Frame: 6 months
    • Differences in breastmilk concentrations of immunity parameters such as immunoglobulins and cytokines from breastmilk of women with or without history of vaginal infection during pregnancy
  • Antimicrobial properties of breastmilk microbiota
    • Time Frame: 6 months
    • Differences in antimicrobial properties against vaginal pathogens using breastmilk of women with or without history of vaginal infection during pregnancy

Participating in This Clinical Trial

Inclusion Criteria

  • Lactating women – Willing to commit throughout the experiment Exclusion Criteria:

  • Long term medication due to certain illnesses for over 3 months during pregnancy – Gestational diabetes during pregnancy – History of diabetes, coronary heart disease, and hypertension in life – BMI before pregnancy above 24.9 – Consuming probiotic product during pregnancy – Consuming probiotic product during lactation period

Gender Eligibility: Female

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Universiti Sains Malaysia
  • Provider of Information About this Clinical Study
    • Principal Investigator: Min-Tze LIONG, Professor – Universiti Sains Malaysia
  • Overall Official(s)
    • Min T Liong, PhD, Principal Investigator, Universiti Sains Malaysia

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.